|
1
|
Thornton HF, Fantaneanu TA, Zhang T, Bercovici E, Hrazdil C, Ikeda KM, Kassiri J, Suller Marti A, Pana R, Rezazadeh A, Kobayashi E, Bui E. Real-world practices in reproductive health and counselling for women with epilepsy: A Canadian perspective. Epilepsy Behav 2024; 151:109623. [PMID: 38262329 DOI: 10.1016/j.yebeh.2024.109623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 12/27/2023] [Accepted: 01/02/2024] [Indexed: 01/25/2024]
Abstract
Canadian women of reproductive potential living with epilepsy present unique care challenges due to the complex interplay of hormones, seizures, and medications. This study explores reproductive health practices and counselling for women with epilepsy. Through a questionnaire developed by the Canadian League Against Epilepsy women with epilepsy (WWE) workgroup, we are the first to report demographic and real-world practice characteristics of Canadian healthcare professionals providing care for WWE with specific focus on family planning, birth plans, and postpartum care counselling. Among respondents, 76.9% routinely reviewed contraception with patients and an intrauterine device (IUD) was the most popular recommended method (85.3%). With regards to preconception planning, 50% of respondents routinely had a preconception drug level prior to pregnancy. A significant proportion, 44.9%, reported not communicating a neurology-informed birth plan to obstetrical health practitioners. The majority recommended breastfeeding for WWE on anti-seizure medications (92.3%) and regularly provided safety counselling for women in the postpartum period (84.6%). Overall, our study demonstrates that Canadian practice patterns conform reasonably well to existing evidence and guidelines, although important gaps in care exist.
Collapse
Affiliation(s)
- Hayley F Thornton
- Department of Neurosciences, University of Calgary, Calgary, Alberta, Canada.
| | - Tadeu A Fantaneanu
- Division of Neurology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, The Ottawa Hospital, Ontario, Canada.
| | - Tinghua Zhang
- Ottawa Hospital Research Institute, The Ottawa Hospital, Ontario, Canada.
| | - Eduard Bercovici
- Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
| | - Chantelle Hrazdil
- Division of Neurology, University of British Columbia, Vancouver Coastal Health, Vancouver, British Columbia, Canada.
| | - Kristin M Ikeda
- Division of Neurology, Department of Medicine, Dalhousie University, Nova Scotia Health, Canada.
| | - Janani Kassiri
- Division of Pediatric Neurology, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
| | - Ana Suller Marti
- Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Pediatrics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
| | - Raluca Pana
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
| | - Arezoo Rezazadeh
- Department of Neurosciences, University of Calgary, Calgary, Alberta, Canada; Division of Neurology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
| | - Eliane Kobayashi
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
| | - Esther Bui
- Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
| |
Collapse
|
|
2
|
Checa-Ros A, Kasteleijn-Nolst Trenite D, Edson-Scott A, Carr B, Cerquiglini A, Seri S. Efficacy of color lenses in abolishing photosensitivity: Beyond the one-type-fits-all approach? Epilepsy Behav 2021; 124:108332. [PMID: 34619544 DOI: 10.1016/j.yebeh.2021.108332] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 09/07/2021] [Accepted: 09/07/2021] [Indexed: 01/19/2023]
Abstract
OBJECTIVE Red-light filtering lenses represent an additional option to medication in photosensitive epilepsy. Blue lenses (Clarlet Z1 F133) can dramatically reduce seizure frequency, with a substantial restriction in luminance that can limit their applicability in daily life. We investigated the efficacy of 4 blue lenses with higher transmittance and reduced chromatic distortion in abolishing the photoparoxysmal EEG response (PPR) compared to the gold-standard Z1 lenses. METHODS We reviewed EEG data during photic-and pattern stimulation in 19 consecutive patients (6-39 years) with photosensitivity (PS). Stimulation was performed at baseline and while wearing Z1 and the four new lenses. Lenses were tested in the same session by asking the patient to wear them in a sequentially randomized fashion while stimulating again with the most provocative photic/pattern stimuli. The primary outcome was the change in the initial PPR observed for each lens, categorized as no change, reduction, and abolition. RESULTS Photosensitivity was detected in 17 subjects (89.5%); pattern sensitivity (PtS) was identified in 14 patients (73.7%). The highest percentages of PPR abolition/reduction were observed with Z1, for both PS and PtS. Regarding the new lenses, B1 + G1 offered the best rates, followed by B1 + G2. B1 + G3 and B1 showed lower efficacy rates, particularly for PtS. In the comparative analysis, no significant differences in PPR suppression were detected between the five lenses for PS. For PtS, the capacity of Z1 for PPR abolition was significantly higher compared with B1 + G3 and B1. CONCLUSIONS This preliminary study suggests efficacy of the new group of blue lenses with potentially greater tolerability, particularly in regions with fewer sunlight hours during winter. In line with the current trend for personalized approach to treatment, this study suggests that in some patients there might be scope in extending the testing to offer the lens with the higher transmittance effective in abolishing the PPR.
Collapse
Affiliation(s)
- A Checa-Ros
- Aston Institute of Health and Neurodevelopment, College of Health and Life Sciences, Aston University, Birmingham, UK; Departamento de Medicina y Cirugía, Universidad CEU Cardenal Herrera, Valencia, Spain
| | - D Kasteleijn-Nolst Trenite
- Department of Neurosurgery and Epilepsy, University Medical Center Utrecht, Utrecht, The Netherlands; Nesmos Department, Faculty of Medicine and Psychology, Sapienza Università, Roma, Italy
| | - A Edson-Scott
- Aston Institute of Health and Neurodevelopment, College of Health and Life Sciences, Aston University, Birmingham, UK
| | - B Carr
- Department of Clinical Neurophysiology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
| | - A Cerquiglini
- Dipartimento di Scienze e Biotecnologie Medico Chirurgiche, Facoltà di Farmacia e Medicina Polo Pontino, Sapienza Università, Roma, Italy
| | - S Seri
- Aston Institute of Health and Neurodevelopment, College of Health and Life Sciences, Aston University, Birmingham, UK; Department of Clinical Neurophysiology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
| |
Collapse
|